Yunjie Dan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yunjie Dan has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Guohong Deng
Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China
7 shared publications - Wenting Tan
Department of Infectious Diseases Southwest Hospital Third Military Medical University Chongqing China
7 shared publications - Wenli Zhao
Institute of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing, 400038, P. R. China
3 shared publications - Qing Mao
Department of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing, China
2 shared publications Shun Tan
Department of Infectious Diseases Southwest Hospital Third Military Medical University Chongqing China
2 shared publications- Yuming Wang
Ocean Univ China, Coll Food Sci & Engn, SKL Marine Food Proc & Safety Control, 1299 Sansha Rd, Qingdao 266404, Peoples R China
2 shared publications
Latest Publications
- 2 December 2013
- Published by Wiley in Hepatology Research
- Vol. 44 (9) , 1000-1007
Effect of HLA‐DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e‐antigen seropositive chronic hepatitis B patients
Aim The reason why the majority of chronic hepatitis B (CHB) patients do not respond to conventional interferon (IFN)‐α or pegylated interferon (PEG IFN) treatment has not been formally demonstrated. The aim of this study was to investigate the association between single nucleotide polymorphisms (SNPs) and response to IFN‐α or PEG IFN therapy in Chinese patients with CHB. Methods Four SNPs among the HLA‐DPA1, HLA‐DPB1 (rs3077 and rs9277535) and IL28B (rs12979860 and rs8099917) regions were genotyped using the MGB‐TaqMan SNP genotyping assay in 144 hepatitis B e‐antigen (HBeAg) seropositive CHB patients who had received 6–12 months IFN‐α or PEG IFN treatment. Patients were classified as responders who achieved any of the four targets: (i) the loss of HBeAg; (ii) anti‐HBe seroconversion; (iii) suppression of hepatitis B virus (HBV) DNA level to below 3 log of baseline; and (iv) alanine aminotransferase normalization. Results By multivariate analysis at 6 months of therapy and 6 months post‐therapy, the results showed that rs3077‐GG genotype was independently associated with higher HBeAg loss rate and anti‐HBe seroconversion rate, and rs9277535‐GG genotype was independently associated with decline of HBV DNA level. However, we did not observe the significant association between SNP near IL28B and the response to IFN‐α or PEG IFN treatment. Conclusion This study suggested that HLA‐DPA1 and HLA‐DPB1 variants were significantly associated with HBeAg loss, anti‐HBe seroconversion and HBV DNA level suppression in HBeAg seropositive CHB patients who received IFN‐α or PEG IFN treatment.
- 2 December 2013
- Published by Wiley in Hepatology Research
- Vol. 44 (9) , 1000-1007
Effect of HLA‐DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e‐antigen seropositive chronic hepatitis B patients
Aim The reason why the majority of chronic hepatitis B (CHB) patients do not respond to conventional interferon (IFN)‐α or pegylated interferon (PEG IFN) treatment has not been formally demonstrated. The aim of this study was to investigate the association between single nucleotide polymorphisms (SNPs) and response to IFN‐α or PEG IFN therapy in Chinese patients with CHB. Methods Four SNPs among the HLA‐DPA1, HLA‐DPB1 (rs3077 and rs9277535) and IL28B (rs12979860 and rs8099917) regions were genotyped using the MGB‐TaqMan SNP genotyping assay in 144 hepatitis B e‐antigen (HBeAg) seropositive CHB patients who had received 6–12 months IFN‐α or PEG IFN treatment. Patients were classified as responders who achieved any of the four targets: (i) the loss of HBeAg; (ii) anti‐HBe seroconversion; (iii) suppression of hepatitis B virus (HBV) DNA level to below 3 log of baseline; and (iv) alanine aminotransferase normalization. Results By multivariate analysis at 6 months of therapy and 6 months post‐therapy, the results showed that rs3077‐GG genotype was independently associated with higher HBeAg loss rate and anti‐HBe seroconversion rate, and rs9277535‐GG genotype was independently associated with decline of HBV DNA level. However, we did not observe the significant association between SNP near IL28B and the response to IFN‐α or PEG IFN treatment. Conclusion This study suggested that HLA‐DPA1 and HLA‐DPB1 variants were significantly associated with HBeAg loss, anti‐HBe seroconversion and HBV DNA level suppression in HBeAg seropositive CHB patients who received IFN‐α or PEG IFN treatment.
- Open Access
- 24 June 2012
- Published by Springer Nature in BMC Medical Genetics
- Vol. 13 (1) , 49
Estrogen receptor alpha gene polymorphisms and risk of HBV-related acute liver failure in the Chinese population
Background: The sexual dimorphism of hepatitis B virus (HBV) -related liver diseases is related with estrogen and its receptors. Recent reports indicate that abnormal expression of estrogen receptor alpha (ESR1) may be a hallmark for the progression of liver disease and HBV carriers presenting variant ESR1 have an extremely aggressive clinical course. Here we examine whether the ESR1 polymorphisms or its haplotypes are related to HBV-related acute liver failure (ALF) risk among chronic HBV carriers in a Chinese population. Methods: A total of 1216 unrelated Han Chinese HBV carriers were recruited in this hospital-based case–control study, including 359 HBV surface antigen (HBsAg) carriers affected with ALF and 857 asymptomatic HBsAg carriers. Two ESR1 haplotype tagging polymorphisms, c.30 T > C (rs2077647) and c.453-397 T > C (rs2234693), were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Results: We observed a significantly increased susceptibility to HBV-ALF associated with the c.30 C allele (P = 8.65 × 10-4), c.453-397 C allele (5.37 × 10-4) and [c.30 C; c.453-397 C] haplotype (Dominant model, P =0.0004, odds ratio = 1.53, 95% CI 1.23 ~ 1.96) compared with the T alleles and [c.30 T; c.453-397 T] haplotype of c.30 T > C and c.453-397 T > C polymorphisms, respectively. Conclusions: Our study suggests that [c.30 C; c.453-397 C] hapotype may be a risk factor for genetic susceptibility to HBV-related ALF in the Chinese population. It also emphasizes the importance of ESR1 in the pathophysiology of HBV-related ALF on the population level.
- 24 June 2012
- Published by Springer Nature in BMC Medical Genetics
- Vol. 13 (1) , 49
Open AccessEstrogen receptor alpha gene polymorphisms and risk of HBV-related acute liver failure in the Chinese population
Background: The sexual dimorphism of hepatitis B virus (HBV) -related liver diseases is related with estrogen and its receptors. Recent reports indicate that abnormal expression of estrogen receptor alpha (ESR1) may be a hallmark for the progression of liver disease and HBV carriers presenting variant ESR1 have an extremely aggressive clinical course. Here we examine whether the ESR1 polymorphisms or its haplotypes are related to HBV-related acute liver failure (ALF) risk among chronic HBV carriers in a Chinese population. Methods: A total of 1216 unrelated Han Chinese HBV carriers were recruited in this hospital-based case–control study, including 359 HBV surface antigen (HBsAg) carriers affected with ALF and 857 asymptomatic HBsAg carriers. Two ESR1 haplotype tagging polymorphisms, c.30 T > C (rs2077647) and c.453-397 T > C (rs2234693), were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Results: We observed a significantly increased susceptibility to HBV-ALF associated with the c.30 C allele (P = 8.65 × 10-4), c.453-397 C allele (5.37 × 10-4) and [c.30 C; c.453-397 C] haplotype (Dominant model, P =0.0004, odds ratio = 1.53, 95% CI 1.23 ~ 1.96) compared with the T alleles and [c.30 T; c.453-397 T] haplotype of c.30 T > C and c.453-397 T > C polymorphisms, respectively. Conclusions: Our study suggests that [c.30 C; c.453-397 C] hapotype may be a risk factor for genetic susceptibility to HBV-related ALF in the Chinese population. It also emphasizes the importance of ESR1 in the pathophysiology of HBV-related ALF on the population level.
- 1 October 2011
- Vol. 19 (10) , 793-4
[Analysis of clinical correlated factors of primary carcinoma of the liver with and without cirrhosis].
- 1 October 2011
- Vol. 19 (10) , 793-4
[Analysis of clinical correlated factors of primary carcinoma of the liver with and without cirrhosis].
- 31 January 2011
- Published by Elsevier in Human Immunology
- Vol. 72 (1) , 69-73
Association of TBX21 promoter polymorphisms with type 1 autoimmune hepatitis in a Chinese population
- 31 January 2011
- Published by Elsevier in Human Immunology
- Vol. 72 (1) , 69-73
Association of TBX21 promoter polymorphisms with type 1 autoimmune hepatitis in a Chinese population
- 1 August 2009
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 13, S71
PP-082 A Cis-acting regulatory variation of estrogen receptor-α and the association with HBV-related liver diseases
- 1 August 2009
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 13, S71
PP-082 A Cis-acting regulatory variation of estrogen receptor-α and the association with HBV-related liver diseases
- 1 February 2009
- Vol. 17 (2) , 91-4
[Analysis of the correlation between the pre-S1 antigen, pre-S2 antigen and DNA of hepatitis B virus in the serum of chronic hepatitis B patients undergoing nucleoside analogue therapy.].
To investigate the dynamic correlation between pre-S1 antigen, pre-S2 antigen and HBV DNA in the serum of chronic hepatitis B (CHB) patients undergoing nucleoside analogue therapy. 12 CHB patients with transient virological response after lamivudine treatment, and 20 patients treated with adefovir for 5 years were recruited in this study. Serum samples were collected at four time points when HBV DNA fluctuated sharply during lamivudine treatment, and at 0, 8, 12, 28, 52, 104, 156, 208, 260 weeks following adefovir treatment. HBV DNA was quantified by real-time PCR, pre-S1 and pre-S2 antigens were detected by ELISA. The titers of pre-S1 and pre-S2 antigens were not correlated with the HBV DNA level in the serum of lamivudine treated patients. Only in one case of the adfovir treated patients, the decrease of pre-S1 and pre-S2 antigens was in parallel with the decrease of HBV DNA. Linear regression analysis indicated that neither pre-S1 antigen nor pre-S2 antigen was correlated with HBV DNA in the serum of lamivudine or adfovir treated patients (P more than 0.05). Our results indicate that the titers of pre-S1 and pre-S2 antigens are not correlated with the serum HBV DNA in CHB patients undergoing nucleoside analogue therapy. Neither pre-S1 nor pre-S2 is a good predictor for the outcome of nucleoside analogue treatment.
- 1 February 2009
- Vol. 17 (2) , 91-4
[Analysis of the correlation between the pre-S1 antigen, pre-S2 antigen and DNA of hepatitis B virus in the serum of chronic hepatitis B patients undergoing nucleoside analogue therapy.].
To investigate the dynamic correlation between pre-S1 antigen, pre-S2 antigen and HBV DNA in the serum of chronic hepatitis B (CHB) patients undergoing nucleoside analogue therapy. 12 CHB patients with transient virological response after lamivudine treatment, and 20 patients treated with adefovir for 5 years were recruited in this study. Serum samples were collected at four time points when HBV DNA fluctuated sharply during lamivudine treatment, and at 0, 8, 12, 28, 52, 104, 156, 208, 260 weeks following adefovir treatment. HBV DNA was quantified by real-time PCR, pre-S1 and pre-S2 antigens were detected by ELISA. The titers of pre-S1 and pre-S2 antigens were not correlated with the HBV DNA level in the serum of lamivudine treated patients. Only in one case of the adfovir treated patients, the decrease of pre-S1 and pre-S2 antigens was in parallel with the decrease of HBV DNA. Linear regression analysis indicated that neither pre-S1 antigen nor pre-S2 antigen was correlated with HBV DNA in the serum of lamivudine or adfovir treated patients (P more than 0.05). Our results indicate that the titers of pre-S1 and pre-S2 antigens are not correlated with the serum HBV DNA in CHB patients undergoing nucleoside analogue therapy. Neither pre-S1 nor pre-S2 is a good predictor for the outcome of nucleoside analogue treatment.
- 1 July 2008
- Vol. 16 (7) , 540-1
[The influence of HBV genotypes on the therapeutic effects of lamivudine in chronic hepatitis B patients].
- 1 July 2008
- Vol. 16 (7) , 540-1
[The influence of HBV genotypes on the therapeutic effects of lamivudine in chronic hepatitis B patients].